TriangleBiospecimen Collection (NCT07301268)
Biospecimen Collection trial for Glioblastoma, IDH-Wildtype (NCT07301268). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or progressive IDH-wildtype glioblastoma or IDH-mutated grade-four astrocytoma who can undergo biopsy and tumor removal.
The idea: randomly give GI-102 alone or with pembrolizumab before surgery. GI-102 combines immune-checkpoint blockade with a modified IL-2 signal to stimulate immune cells. Pembrolizumab blocks PD-1. Treatment continues after surgery; pembrolizumab may then be added in the GI-102-only group. Researchers compare immune cells in biopsy and surgical tissue, rather than assuming tumor shrinkage.
This phase 2 study plans 36 patients. Jian Campian leads Mayo Clinic's recruiting Rochester site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.